martes, 1 de mayo de 2018

Melanoma/Skin Cancer Detection and Prevention Month® (see related measures) 1 | National Quality Measures Clearinghouse 1/3

Search | National Quality Measures Clearinghouse

nqmc

Health Awareness Topics: May 2018

  • MEASURE SUMMARY
    •  
  • NQMC:011264
    •  
  • 2016 FEB

Cutaneous melanoma: proportion of patients with cutaneous melanoma who undergo diagnostic excision biopsy where the surgical pathology report contains a full set of data items (as defined by the current Royal College of Pathologists dataset).

NHS Scotland; Scottish Cancer Taskforce
  • MEASURE SUMMARY
    •  
  • NQMC:011270
    •  
  • 2016 FEB

Cutaneous melanoma: proportion of patients with cutaneous melanoma undergoing wide local excision within 84 days of their diagnostic excision biopsy.

NHS Scotland; Scottish Cancer Taskforce
  • MEASURE SUMMARY
    •  
  • NQMC:011174
    •  
  • 2016 NOV

Melanoma: percentage of patients, regardless of age, with a current diagnosis of stage 0 through IIC melanoma or a history of melanoma of any stage, without signs or symptoms suggesting systemic spread, seen for an office visit during the one-year measurement period, for whom no diagnostic imaging studies were ordered.

American Academy of Dermatology; National Committee for Quality Assurance; Physician Consortium for Performance Improvement®
  • MEASURE SUMMARY
    •  
  • NQMC:007191
    •  
  • 2009 NOV

Melanoma: percentage of patients with a melanoma less than or equal to 1 mm thick (i.e., T1) for whom the surgical excision margins are 1 cm (or the specific anatomic or cosmetic factors that limit margin distance are noted).

American College of Surgeons
  • MEASURE SUMMARY
    •  
  • NQMC:007211
    •  
  • 2009 NOV

Melanoma: percentage of patients with melanoma who have biopsy-proven, palpable nodal disease who do not undergo sentinel lymph node biopsy (SLNB).

American College of Surgeons
  • MEASURE SUMMARY
    •  
  • NQMC:011267
    •  
  • 2016 FEB

Cutaneous melanoma: proportion of patients with cutaneous melanoma who undergo sentinel node biopsy (SNB) where the SNB report contains a full set of data items (as defined by the current Royal College of Pathologists dataset).

NHS Scotland; Scottish Cancer Taskforce
  • MEASURE SUMMARY
    •  
  • NQMC:007188
    •  
  • 2009 NOV

Melanoma: percentage of patients with a melanoma in situ (i.e., Tis) for whom the surgical excision margins are 5 mm (or the specific anatomic or cosmetic factors that limit margin distance are noted).

American College of Surgeons
  • MEASURE SUMMARY
    •  
  • NQMC:007194
    •  
  • 2009 NOV

Melanoma: percentage of patients to undergo a sentinel lymph node biopsy (SLNB) for melanoma for whom lymphoscintigraphy is performed to identify the draining nodal basin(s) when drainage to more than one basin is possible.

American College of Surgeons
  • MEASURE SUMMARY
    •  
  • NQMC:007200
    •  
  • 2009 NOV

Melanoma: percentage of patients who undergo an axillary lymph node dissection (LND) or completion lymph node dissection (CLND) for melanoma for whom at least 10 regional lymph nodes are resected and pathologically examined.

American College of Surgeons
  • MEASURE SUMMARY
    •  
  • NQMC:007197
    •  
  • 2009 NOV

Melanoma: percentage of patients who have a stage Ib or II melanoma with whom sentinel lymph node biopsy (SLNB) is discussed.

American College of Surgeons
  • MEASURE SUMMARY
    •  
  • NQMC:011273
    •  
  • 2016 FEB

Cutaneous melanoma: proportion of patients with stage III and IV cutaneous melanoma who undergo CT or positron emission tomography (PET) CT prior to completion lymphadenectomy.

NHS Scotland; Scottish Cancer Taskforce
  • MEASURE SUMMARY
    •  
  • NQMC:007206
    •  
  • 2009 NOV

Melanoma: percentage of patients who have a resected primary melanoma metastatic to regional lymph nodes or distant sites for whom there is a documented discussion regarding adjuvant therapy.

American College of Surgeons
  • MEASURE SUMMARY
    •  
  • NQMC:007189
    •  
  • 2009 NOV

Melanoma: percentage of patients with a melanoma for whom the surgeon documented the measured surgical margin in the operative report.

American College of Surgeons
  • MEASURE SUMMARY
    •  
  • NQMC:007209
    •  
  • 2009 NOV

Melanoma: percentage of patients with melanoma having biopsy-proven or palpable nodal disease and no evidence of distant metastases who undergo a lymph node dissection (LND).

American College of Surgeons
  • MEASURE SUMMARY
    •  
  • NQMC:011265
    •  
  • 2016 FEB

Cutaneous melanoma: proportion of patients with cutaneous melanoma who are discussed at a multidisciplinary team (MDT) meeting before definitive treatment.

NHS Scotland; Scottish Cancer Taskforce
  • MEASURE SUMMARY
    •  
  • NQMC:011011
    •  
  • 2016 NOV

Melanoma: percentage of patient visits, regardless of age, with a new occurrence of melanoma that have a treatment plan documented in the chart that was communicated to the physician(s) providing continuing care within one month of diagnosis.

American Academy of Dermatology; National Committee for Quality Assurance; Physician Consortium for Performance Improvement®
  • MEASURE SUMMARY
    •  
  • NQMC:011268
    •  
  • 2016 FEB

Cutaneous melanoma: proportion of patients with cutaneous melanoma undergoing diagnostic excision biopsy who undergo a wide local excision.

NHS Scotland; Scottish Cancer Taskforce
  • MEASURE SUMMARY
    •  
  • NQMC:007195
    •  
  • 2009 NOV

Melanoma: percentage of patients who undergo a sentinel lymph node biopsy (SLNB) for melanoma for whom the sentinel lymph nodes (SLNs) are sent for permanent sectioning only (no frozen sections), unless a reason is documented.

American College of Surgeons
  • MEASURE SUMMARY
    •  
  • NQMC:007192
    •  
  • 2009 NOV

Melanoma: percentage of patients with a melanoma 1-2 mm thick (i.e., T2) for whom the surgical excision margins are 1-2 cm (or the specific anatomic or cosmetic factors that limit margin distance are noted).

American College of Surgeons
  • MEASURE SUMMARY
    •  
  • NQMC:007212
    •  
  • 2009 NOV

Melanoma: percentage of patients treated for melanoma for whom stage-specific follow-up, including future skin exams, is discussed and documented.

American College of Surgeons
Publicado por en

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)